Phaarmasia Limited (BOM:523620)
81.86
-0.41 (-0.50%)
At close: Mar 4, 2026
Phaarmasia Revenue
Phaarmasia had revenue of 160.51M INR in the quarter ending December 31, 2025, with 239.94% growth. This brings the company's revenue in the last twelve months to 449.06M, up 55.23% year-over-year. In the fiscal year ending March 31, 2025, Phaarmasia had annual revenue of 243.69M, down -20.35%.
Revenue (ttm)
449.06M
Revenue Growth
+55.23%
P/S Ratio
1.24
Revenue / Employee
12.47M
Employees
36
Market Cap
558.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 243.69M | -62.25M | -20.35% |
| Mar 31, 2024 | 305.93M | 31.04M | 11.29% |
| Mar 31, 2023 | 274.90M | 102.74M | 59.68% |
| Mar 31, 2022 | 172.16M | -31.79M | -15.59% |
| Mar 31, 2021 | 203.95M | -40.98M | -16.73% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mangalam Drugs & Organics | 2.38B |
| Godavari Drugs | 986.94M |
| Accretion Pharmaceuticals | 826.43M |
| Walpar Nutritions | 757.46M |
| Onyx Biotec | 663.87M |
| Shelter Pharma | 598.96M |
| Panjon | 493.34M |
| Rajnish Wellness | 455.79M |